Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Psoriatic Arthritis

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study

Semin Arthritis Rheum.

Coates LC, Nash P, Kvien TK, Gossec L, Mease PJ, Rasouliyan L, Pricop L, Jugl SM, Gandhi KK, Gaillez C, Smolen JS

doi: 10.1016/j.semarthrit.2020.03.015.

Psoriatic Arthritis

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).

Ann Rheum Dis.

Strand V, Mease P, Gossec L, Elkayam O, van den Bosch F, Zuazo J, Pricop L, Mpofu S; FUTURE 1 study group

doi: 10.1136/

COMMENTED

Psoriatic Arthritis

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5

★ 3 Recommended and commented by Dr Heino Prillwitz, Faculty Member

Rheumatology (Oxford).

van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L

doi: 10.1093/rheumatology/kez420.

Atopic Dermatitis

Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials

Dermatol Ther (Heidelb).

Simpson EL

doi: 10.1007/s13555-017-0181-6.

Psoriatic Arthritis

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies

J Eur Acad Dermatol Venereol.

Merola JF, Papp KA, Nash P, Gratacós J, Boehncke WH, Thaçi D, Graham D, Hsu MA, Wang C, Wu J, Young P

doi: 10.1111/jdv.16433.

Rheumatoid ArthritisSystemic Lupus Erythematosus

Rheumatoid arthritis patients achieved better quality of life than systemic lupus erythematosus patients at sustained remission

Clin Exp Rheumatol.

Pascual-Ramos V, Contreras-Yáñez I, Valencia-Quiñones KR, Romero-Díaz J

COMMENTED

Psoriasis

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Am J Clin Dermatol.

Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA

doi: 10.1007/s40257-018-0396-z.

AcnePsoriasis

Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

Br J Dermatol

Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM

doi: 10.1111/bjd.20568

Psoriatic Arthritis

Association between enthesitis and health-related quality of life in psoriatic arthritis in anti-TNF-naïve patients from two Phase 3 ustekinumab trials

J Rheumatol.

McInnes IB, Puig L, Gottlieb AB, Ritchlin C, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A, PSUMMIT 1 and 2 Study

doi: 10.3899/jrheum.180792.

Related content

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5

Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies

Rheumatoid arthritis patients achieved better quality of life than systemic lupus erythematosus patients at sustained remission

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

Association between enthesitis and health-related quality of life in psoriatic arthritis in anti-TNF-naïve patients from two Phase 3 ustekinumab trials